AUTHORS
Mengyuan Liu, MD, Kexing Ren2, Liqun Zou, MD3, Ming Jiang, MD4, Li Xie5, Na Li6, Chunli Yang Jr, MD,PHD7, Xi Chen, MD8, You Feng9, Tao Hai Jr, MD,PHD10
AFFILIATIONS
1 West China Hospital of Sichuan University, Cheng Du, SiChuan, China
2 West China Hospital of Sichuan University, Cheng Du, SiChuan, China
3 West China Hospital of Sichuan University, Cheng Du, SiChuan, China
4 West China Hospital of Sichuan University, Cheng Du, SiChuan, China
5 West China Hospital of Sichuan University, Cheng Du, SiChuan, China
6 West China Fourth Hospital, Sichuan University, Cheng Du, China
7 West China Hospital of Sichuan University, Cheng Du, SiChuan, China
8 West China Hospital of Sichuan University, Cheng Du, SiChuan, China
9 West China Fourth Hospital, Sichuan University, Cheng Du, China
10 West China Hospital of Sichuan University, Cheng Du, SiChuan, China
ABSTRACT
Background:
Treatment selection for older patients with primary central nervous system lymphoma (PCNSL) remains challenging, and real-world evidence regarding novel-agent-containing frontline therapy in this population is limited. Older patients are underrepresented in prospective trials and often have competing vulnerabilities that influence both induction intensity and consolidation feasibility. Bruton tyrosine kinase inhibitors (BTK inhibitors) and immunomodulatory agents are increasingly incorporated into induction regimens, but their associations with response depth, survival, and post-induction treatment patterns remain incompletely defined. We evaluated outcomes according to frontline induction strategy in patients aged >=60 years with PCNSL.
Methods:
We retrospectively analyzed 145 newly diagnosed PCNSL patients aged >=60 years from a multicenter PCNSL database. Patients were categorized as receiving traditional induction therapy or novel-containing induction therapy, defined as incorporation of a BTK inhibitor and/or lenalidomide. Response was assessed after two cycles and at end of treatment (EOT). Progression-free survival (PFS) and overall survival (OS) were calculated from initiation of frontline therapy. Multivariable Cox models adjusted for prespecified baseline prognostic factors, including age >=70 years, ECOG performance status >=2, deep brain involvement, multiple lesions, and double-expression status. Inverse probability of treatment weighting (IPTW) and response-adjusted models were performed as sensitivity analyses. Baseline balance and treatment-effect estimates were interpreted with emphasis on clinical plausibility rather than hypothesis testing alone. Among patients achieving EOT complete response (CR) or partial response (PR), post-induction treatment patterns were explored descriptively.
Results:
Among 145 eligible patients, 40 received traditional induction and 105 received novel-containing induction. Novel-containing induction was associated with higher response rates. After two cycles, the CR/PR rate was 91.4% versus 71.0% (adjusted odds ratio [OR], 4.74; P=0.006). At EOT, the CR/PR rate was 76.2% versus 56.4% (adjusted OR, 2.55; P=0.023), and the CR rate was 57.1% versus 30.8% (adjusted OR, 3.02; P=0.008).
With a median follow-up of 42.0 months, median PFS was 48.8 versus 16.5 months, and median OS was not reached versus 19.5 months in the novel-containing and traditional groups, respectively. In the prespecified multivariable Cox model, novel-containing induction was associated with improved OS (hazard ratio [HR], 0.42; 95% CI, 0.23-0.78; P=0.006). The association with PFS was favorable but not statistically significant after adjustment (HR, 0.65; 95% CI, 0.36-1.17; P=0.148). IPTW analyses showed consistent directionality for OS, although statistical significance varied by model specification. After adjustment for EOT response, the association between novel-containing induction and survival was attenuated, suggesting that response depth may partly explain the observed survival difference.
Among 102 patients achieving EOT CR/PR, post-induction treatment patterns differed by induction strategy. Post-induction treatment was defined as maintenance therapy, consolidative radiotherapy, or autologous stem cell transplantation (ASCT)-containing consolidation after EOT. Any post-induction treatment was more frequent in the novel-containing group than in the traditional group (77.5% vs 50.0%). Descriptively, novel-containing induction followed by any post-induction treatment showed the highest 2-year OS alive proportion (95.2%) and a favorable 2-year PFS event-free proportion (85.5%). Because post-induction therapy was selected after induction response, these findings are exploratory.
Conclusions:
In this multicenter retrospective cohort of older patients with PCNSL, frontline novel-containing induction therapy was associated with deeper response and improved OS compared with traditional induction therapy, whereas the adjusted association with PFS was less robust. Sensitivity analyses supported a consistent OS direction, and response-adjusted models suggested that deeper response may contribute to the observed survival association. Exploratory post-induction analyses suggested that treatment trajectories after EOT CR/PR may differ by initial induction strategy. Prospective studies are warranted to define optimal induction and post-induction strategies for older patients with PCNSL.
DISCLOSURES
Mengyuan Liu, MD: No relevant conflicts of interest to declare.